Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro Pfizer Oncology, Pfizer Inc., New York, NY, USAMiller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), y...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/df7e828356464b2fad8d887cda21e1aa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:df7e828356464b2fad8d887cda21e1aa |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:df7e828356464b2fad8d887cda21e1aa2021-12-02T06:11:54ZResponse to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib1177-5491https://doaj.org/article/df7e828356464b2fad8d887cda21e1aa2015-02-01T00:00:00Zhttp://www.dovepress.com/resistant-mutations-in-cml-and-phall-ndash-role-of-ponletter-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491 Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro Pfizer Oncology, Pfizer Inc., New York, NY, USAMiller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), yet by the omission of an approved agent within the same class of drugs, provided an inaccurate summary of the current treatment landscape for CML. View original paper by Miller and colleagues.Bardy-Bouxin NMatczak EDevgan GWoloj MShapiro MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 23-24 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Bardy-Bouxin N Matczak E Devgan G Woloj M Shapiro M Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib |
| description |
Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro Pfizer Oncology, Pfizer Inc., New York, NY, USAMiller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), yet by the omission of an approved agent within the same class of drugs, provided an inaccurate summary of the current treatment landscape for CML. View original paper by Miller and colleagues. |
| format |
article |
| author |
Bardy-Bouxin N Matczak E Devgan G Woloj M Shapiro M |
| author_facet |
Bardy-Bouxin N Matczak E Devgan G Woloj M Shapiro M |
| author_sort |
Bardy-Bouxin N |
| title |
Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib |
| title_short |
Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib |
| title_full |
Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib |
| title_fullStr |
Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib |
| title_full_unstemmed |
Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib |
| title_sort |
response to miller et al: resistant mutations in cml and ph(+) all – role of ponatinib |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/df7e828356464b2fad8d887cda21e1aa |
| work_keys_str_mv |
AT bardybouxinn responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib AT matczake responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib AT devgang responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib AT wolojm responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib AT shapirom responsetomilleretalresistantmutationsincmlandphallndashroleofponatinib |
| _version_ |
1718400080277405696 |